Ongororo Yekubudirira Inosimbisa Kuchengeteka uye Kushanda Kwekurapa kweCD19/CD20 CAR-T paR/R B-NHL

Chidzidzo chitsva chakaburitswa mu Ropainoratidza kubudirira kwekuvandudzwa kweprizloncabtagene autoleucel (prizlon-cel), mushonga mutsva weCD19/CD20-targeting CAR-T cell therapy, wekurapa B-cell inodzokera shure/inoramba kushanda. Lymphoma isiri yeHodgkin (r/r B-NHL). Kuedzwa uku, chidzidzo chechikamu chekutanga, chenzvimbo dzakawanda, chakavhurika chakaitwa muChina, chinopa ruzivo rwakavimbika pamusoro pekuchengetedzeka uye kushanda kwenzira iyi ine zvinangwa zviviri.

Chidzidzo ichi chakatungamirirwa nechikwata chevaongorori vakakurumbira vanobva kumasangano anosanganisira Chipatara Chekutanga Chinobatanidza Cheyunivhesiti yeZhejiang neYunivhesiti yeTongji, chakanyoresa varwere makumi mana nevasere vane r/r B-NHL, vazhinji vavo vakakura. B-Cell Lymphoma (LBCL). Varwere vakamborapwa nepakati pemitsetse mitatu. Vatori vechikamu vakapinzwa mushonga weprizlon-cel kamwe chete mushure mekupiwa chemotherapy ye lymphodepleting, ine madosi akasiyana-siyana pamatanho matatu (DL1, DL2, uye DL3).

Zvakawanikwa Zvikuru:

• Nhoroondo Yekuchengetedza: Hapana toxicities dzinoderedza dose (DLT) dzakaonekwa, uye kurapwa kwacho kwakaratidza migumisiro inogoneka. Cytokine release syndrome (CRS) yakaitika mu93.8% yevarwere, vazhinji vegiredhi 1-2, nemurwere mumwe chete wegiredhi 3. Immune effector cell-associated neurotoxicity syndrome (ICANS) yaisawanzoitika uye yakanga isina kunyanyisa, isina zviitiko zvegiredhi 3 kana kupfuura.
• Kushanda zvakanaka: Muyero wemhinduro yose (ORR) we91.5% wakawanikwa, nechiyero chemhinduro yakazara (CR) che85.1%. Pakati pevarwere veLBCL, mwero weORR neCR waiva 90.7% uye 86.0%, zvichiteerana. Zvinoshamisa kuti, 48.9% yevarwere vakaramba vaine CR pakutevera kwekupedzisira, uye vamwe vakapindura kupfuura makore matatu.
• Mhedzisiro Yekupona: Kaplan-Meier anofungidzira kuti huwandu hwemhinduro (DOR) hwakagara kwemakore maviri, hupenyu husina kuenderera mberi (PFS), uye huwandu hwehupenyu hwese (OS) hwaiva 66.0%, 62.6%, uye 76.5% zvichiteerana. Muvarwere veCR, huwandu uhwu hwakatokwira.

Prizlon-cel yakaratidza kukura kwakasimba uye kugara kwenguva refu, ine nguva yepakati yekupora kwemasero eB yemazuva 185. Dhizaini yayo ine zvinangwa zviviri inotarisa kubuda kweantigen, nzira yakajairika yekudzivirira mabhakitiriya mukurapa kweCAR-T.